FDI-6 Inhibits the Expression and Function of FOXM1 to Sensitize BRCA-Proficient Triple-Negative Breast Cancer Cells to Olaparib by Regulating Cell Cycle Progression and DNA Damage Repair

Scientists found that repression of the oncogenic transcription factor FOXM1 using FOXM1 shRNA or FOXM1 inhibitor FDI-6 could sensitize BRCA-proficient TNBC to PARP inhibitor Olaparib in vitro and in vivo.